Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Wow - click on virtual-clinic and read - very impressive
View:
Post by GRAMPS1996 on Dec 31, 2021 5:19pm

Wow - click on virtual-clinic and read - very impressive

C.V. Dr. Vera Madzarevic | virtual-clinical

https://www.edupharma-virtual.com/c-v-dr-vera-madzarevic

Dr. Vera M. Madzarevic . ... (Novartis, NJ, US.) awarded the “Business Excellence Award Certificate”. Establishment and oversight of complete development, review and evaluation of

Comment by Scorpio2 on Dec 31, 2021 5:44pm
I stopped  at Leadership for M&A. That's all I needed to know !!! All the rest.... impressive to say the least.
Comment by Rumpl3StiltSkin on Dec 31, 2021 8:07pm
Dr. Mad is the real deal, a heavy hitter. Good job TLT Management!!
Comment by StevenBirch on Dec 31, 2021 8:21pm
I am not saying that they intentionally brought in substandard people before but I think by bringing in someone of her obvious quality shows how close they think they are. And let's not forget when Roger got slapped on the wrist their hands were tied but they have shown the ability to adjust on the fly, first with trial missteps and now with management hires. As for portfolio weighting I' ...more  
Comment by CancerSlayer on Jan 01, 2022 12:47am
  I also can't ignore the fact that someone of her stature & reputation would be VERY selective in who she joins.  She is an evidence-based scientist at heart & her decision was more than likely about having the opportunity to guide & be associated with groundbreaking tech.  I don't think she would sign on to anything less, even if the money was right...all imo ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250